Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Falciparum malaria protein 11 (FMP011) + AS02A is an experimental vaccine candidate for the prevention of *Plasmodium falciparum* malaria. FMP011 is a recombinant protein consisting of a 54-kDa, 456-amino-acid polypeptide derived from the N-terminal region of the *P. falciparum* apical membrane antigen-1 (AMA1), which plays a key role in erythrocyte invasion by the parasite[5]. The vaccine formulation includes the adjuvant system AS02A, designed to enhance immune responses. In clinical studies, this combination has been shown to induce strong antibody and cellular immune responses against AMA1 but did not prevent parasitemia following controlled human malaria infection[4][5]. The primary indication is for prophylaxis against *P. falciparum* malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on falciparum malaria protein 11 + AS02A.